Search Results

Portal Biotechnologies, Inc., a cell engineering platform company, announced a $5M pre-seed round led by Pear VC, with participation from Conscience VC and 10x Capital.

Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics, announced that it is engaged in a process to explore strategic alternatives to maximize shareholder value.

Pear Therapeutics, Inc. announced that the Company and its wholly owned subsidiary, Pear Therapeutics, Inc. each voluntarily filed for protection under chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware and they intend to pursue a sale of the business or assets under section 363 of the Bankruptcy Code.

Pear Therapeutics and COEUS Healthcare Partner to Combat the Addiction Crisis With Prescription Digital Therapeutics.

Pear Therapeutics, Inc. today announced the Company will participate in the 43rd Annual Cowen Healthcare Conference being held March 6-8, 2023 in Boston.

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported results for its third quarter ended September 30, 2022.

Pear Therapeutics, Inc. (Nasdaq: PEAR) today announced the company will participate in the Credit Suisse 31st Annual Healthcare Conference in Rancho Palos Verdes, California.

Spero Health, one of the nation’s largest office-based outpatient opioid treatment providers for individuals in recovery, to expand patient access to Pear’s prescription digital therapeutics (PDTs) for the treatment of substance use disorder (SUD) and opioid use disorder (OUD).

Pear Therapeutics Announces Inclusion of reSET ® and reSET-O ® on the January 2023 Florida Medicaid Preferred Drug List.

Pear Therapeutics, Inc. today announced the company will participate in the LifeSci Partners HealthTech Symposium on September 20, 2022.